№ lp_1_10181
File format: docx
Character count: 32534
File size: 197 KB
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Publications gateway number:
GOV-16528
Reference number:
PPV23 PGD
Version:
5.00
Valid from:
1 September 2024
Review date:
1 September 2026
Expiry date:
1 March 2027
Vaccine:
23-valent pneumococcal polysaccharide vaccine (PPV23)
Programme:
National immunisation programme against pneumococcal disease
Target population:
Individuals aged 65 years and over and individuals aged 2 years and over in clinical risk groups
Geographical scope:
England
Legal framework:
Human Medicines Regulations 2012, Schedule 16 Part 2
Issuing organisation:
UK Health Security Agency
Developing body:
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
Authors:
Christina Wilson; Professor Shamez Ladhani; David Green
Approval status:
Ratified by the UKHSA Medicines Governance Committee
Document type:
Patient Group Direction
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2017
Region / city:
Australia
Theme:
Meningococcal Vaccination
Document Type:
Application for Vaccine Listing
Organization / institution:
National Immunization Program (NIP)
Author:
Pfizer Australia Pty Ltd
Target Audience:
Health professionals, adolescents, school-based vaccination program administrators
Validity Period:
Not specified
Approval Date:
29 August 2013
Amendment Date:
Not specified
Note:
Contextual description
Year:
2016
Region / City:
Australia
Theme:
Pneumococcal disease prevention
Document Type:
Submission
Organization / Institution:
Pfizer Australia Pty Ltd
Author:
Pfizer Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers, public health authorities
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2023
Region / city:
Australia
Topic:
Pneumococcal vaccination
Document type:
Submission
Agency / organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Healthcare professionals involved in immunization
Period of validity:
Not specified
Approval date:
Expected by 30 April 2023
Date of changes:
9 February 2023
Year:
2016
Region / City:
Australia
Theme:
Pneumococcal disease prevention
Document Type:
Submission
Organization / Institution:
Pfizer Australia Pty Ltd
Author:
Pfizer Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers, public health authorities
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Location:
Lille, France
Topic:
Interaction and reactivity of atmospheric pollutants in porous materials
Document type:
PhD proposal
Institution:
Laboratory of Spectroscopy for Interactions, Reactivity and Environment (LASIRE), University of Lille
Collaborating institution:
Hybrid Materials (MATHYB) team, Unité de Catalyse et Chimie du Solide (UCCS)
Supervisor:
Pr. Alain Moissette
Target audience:
PhD candidates in Chemistry or Physical Chemistry
Funding:
Planned co-funding from Region Hauts de France
Required qualifications:
Master in Chemistry or Physical Chemistry, specialization in micro- and nano-porous materials or photochemistry and spectroscopy of solids
Keywords:
Metal Organic Framework (MOF), vibrational optical spectroscopy, time-resolved spectroscopy
Application procedure:
Submission of CV, motivation letter, and academic transcripts
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Publications gateway number:
GOV-16528
Reference number:
PPV23 PGD
Version:
5.00
Valid from:
1 September 2024
Review date:
1 September 2026
Expiry date:
1 March 2027
Vaccine:
23-valent pneumococcal polysaccharide vaccine (PPV23)
Programme:
National immunisation programme against pneumococcal disease
Target population:
Individuals aged 65 years and over and individuals aged 2 years and over in clinical risk groups
Geographical scope:
England
Legal framework:
Human Medicines Regulations 2012, Schedule 16 Part 2
Issuing organisation:
UK Health Security Agency
Developing body:
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
Authors:
Christina Wilson; Professor Shamez Ladhani; David Green
Approval status:
Ratified by the UKHSA Medicines Governance Committee
Document type:
Patient Group Direction
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2023
Region / city:
Australia
Subject:
Pneumococcal vaccine
Document type:
Submission
Organ / institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Pfizer Australia Pty Ltd
Target audience:
Healthcare professionals, public health policymakers
Period of validity:
Ongoing
Approval date:
27 April 2023 (FDA approval)
Amendment date:
20 December 2022 (TGA submission)
Background:
This document presents the submission for the 20-valent pneumococcal conjugate vaccine to be listed on the National Immunisation Program in Australia for specific paediatric populations.
Year:
2019
Region / City:
Australia
Topic:
Invasive Pneumococcal Disease, Vaccination, Disease Surveillance
Document Type:
Surveillance Report
Organization / Institution:
Communicable Diseases Network Australia
Author:
Kate Pennington, Enhanced Invasive Pneumococcal Disease Surveillance Working Group
Target Audience:
Public Health Officials, Healthcare Providers
Period of Validity:
1 April 2019 – 30 June 2019
Approval Date:
Not specified
Date of Changes:
Not specified
Description:
Report on invasive pneumococcal disease incidence, vaccination impact, and seasonal variations across Australia for the second quarter of 2019.
Year:
2023
Region / city:
Australia
Topic:
Pneumococcal vaccination
Document type:
Submission
Agency / organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Healthcare professionals involved in immunization
Period of validity:
Not specified
Approval date:
Expected by 30 April 2023
Date of changes:
9 February 2023
Year:
2016
Region / City:
Australia
Theme:
Pneumococcal disease prevention
Document Type:
Submission
Organization / Institution:
Pfizer Australia Pty Ltd
Author:
Pfizer Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers, public health authorities
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2014
Region / City:
United States
Subject:
Pneumococcal immunization and health reminders
Document Type:
Installation and Setup Guide
Institution:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Healthcare professionals in the Veterans Affairs system
Validity Period:
Ongoing updates for system usage
Approval Date:
February 2014
Modification Date:
Not specified
Year:
2020
Region / City:
Australia
Topic:
Pneumococcal Vaccination Recommendations
Document Type:
Public Consultation
Organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target Audience:
Healthcare professionals, general public, stakeholders in immunization policies
Period of Validity:
2020 and beyond
Approval Date:
Not specified
Date of Changes:
March 2020
Contextual Description:
Public consultation document outlining proposed changes to the recommended use of pneumococcal vaccines, aimed at improving vaccination guidelines and access for high-risk populations.
Document type:
Supplementary tables
Subject:
ICD-9-CM diagnostic codes for pneumococcal diseases and comorbidities
Disease categories:
Invasive pneumococcal disease (IPD), non-IPD pneumococcal infections, acute otitis media (AOM), otitis media with effusion (OME), AOM complications
Classification system:
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
Content structure:
Disease type, clinical condition, ICD-9-CM code or code combinations, description
Clinical focus:
Pneumococcal infections and related complications
Additional dataset:
ICD-9-CM codes for prior comorbidities
Comorbidity categories:
Neurological, cardiovascular, lung, liver, kidney, metabolic, immunological conditions
Purpose:
Study cohort identification using diagnostic codes
Abbreviations:
IPD (Invasive Pneumococcal Diseases), PNI (Pneumococcal Infections), AOM (Acute Otitis Media), OME (Otitis Media with Effusion)